Health Economics & Outcomes Research Fellowships

2024-2026
Novartis is a world leader in the research and development of products to protect and improve health and well-being.

Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz. Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing, and marketing prescription drugs to prevent and cure diseases, to ease suffering and to enhance quality of life. Novartis’ portfolio of products is directed toward cardiovascular, multiple sclerosis, immunology, hepatology, and dermatology, organ transplantation, ophthalmology, oncology and hematology, and other therapeutic areas.

Novartis, derived from the Latin novae artes, meaning “new skills,” is committed to using new skills to improve health and well-being through innovative products and services. Recognizing an increasing need for outcomes information, resources and expertise, the Health Economics & Outcomes Research (HEOR) departments at Novartis strive to be best-in-class in the generation of outcomes evidence that demonstrates value and optimizes patient access to Novartis products. This is accomplished through execution of burden and cost-of-illness studies, economic evaluations alongside clinical trials, comparative effectiveness research, cost-effectiveness analyses, prospective observational studies such as effectiveness registries, retrospective claims database analyses and patient-reported outcomes research.
Purpose

The Health Economics & Outcomes Research (HEOR) Fellowship Program provides training and hands-on experience in a broad range of health economics, outcomes research and comparative effectiveness research (CER) opportunities. This 2-year program is structured to allow the Fellows to gain proficiency in the field of health economics, outcomes research and CER as conducted in academic, managed care, hospital, health policy and/or pharmaceutical industry settings.
Overview

Novartis Pharmaceuticals Corporation is pleased to offer three 2-year Health Economics & Outcomes Research (HEOR) Fellowship positions for the 2024-2026 cycle.

The objective of the first year is to educate the fellow on general principles and methods applied in health economics and outcomes research. Concurrently, the fellow will participate in ongoing outcomes research projects at the first year fellowship site. All Fellows will spend the second year of the Fellowship at the US-based headquarters of Novartis Pharmaceuticals Corporation located in East Hanover, New Jersey.

While at Novartis, "field-based" training will be undertaken as part of the Fellowship training. Fellows will participate in health economics and outcomes research projects and gain experience in how a pharmaceutical manufacturer uses clinical, economic, and humanistic data to support the development and commercialization of its products, with opportunities in dermatology, cardiovascular franchises and renal franchises.

The fellowship positions differ by first-year site requirements and type of experience offered. Each position is described in this brochure. Compensation includes a competitive stipend, basic medical insurance, holiday and vacation time, plus other benefits associated with each specific academic/managed care institution.

First-Year Fellowship Sites for 2-Year Programs (3 Positions):

• Baylor Scott & White Health, Temple, TX/ The University of Texas at Austin, Austin, TX (1 position)
• Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA (1 position)
• University of Pittsburgh School of Pharmacy/UPMC Health Plan, Pittsburgh, PA (1 position)

Fellowship Alumni: Where Are They Now?

30% Biopharma/Start-up
45% Pharma
8% PBM/Payer
5% Hospital & Healthcare
5% Consulting
5% Academia
2% Retail

Contact

Please contact current Fellows for any site-specific questions (contact information provided on subsequent pages).

For inquiries regarding general application or interview process, please contact:

Batul Electricwala, PhD, BPharm
Director, HE&OR and HE&OR Fellowship Director
East Hanover, NJ
usheor.fellowship@novartis.com
Novartis Pharmaceuticals Corporation/
Baylor Scott & White Health/
The University of Texas at Austin

Fellowship Sites & Preceptors

Baylor Scott & White Health
Paul Godley, PharmD, FASHP, BCPS, Director of Pharmacy, Ambulatory & Specialty Clinical Pharmacy Services, Temple, TX

The University of Texas at Austin College of Pharmacy
Chanhyun Park, PhD, MPharm, MEd, RPh, Assistant Professor of Health Outcomes, Austin, TX

Novartis Pharmaceuticals Corporation
Batul Electricwala, PhD, BPharm, Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

Baylor Scott & White is an integrated healthcare system in central Texas. The Scott & White Health Plan is a health maintenance organization that has over 400,000 members and is affiliated with the Baylor Scott & White Quality Alliance, the system’s accountable care organization, which represents over 6,000 physicians. Baylor Scott & White is affiliated with the College of Medicine, Texas A&M University Health Science Center, and the College of Pharmacy, The University of Texas at Austin.

The Department of Pharmacy at Baylor Scott & White provides progressive and innovative pharmaceutical services in a variety of environments for all components of the institution. Included are clinical and distributive services for the hospital, clinic and health plan, as well as sponsorship of pharmaceutical care programs and ambulatory care clinics focusing on lipid, diabetes and anticoagulation management. Fellows will gain significant understanding of the key issues involved in pharmacy services provided by prescription benefits management and managed care organizations. The integrated character of the institution and the Department of Pharmacy provides significant opportunities for pharmacy practice, research and education.

The Health Outcomes and Pharmacy Practice Division, College of Pharmacy, The University of Texas at Austin, is one of the preeminent educational institutions for pharmacy education in the nation. The college is located in downtown Austin, and the Fellow is offered the option of pursuing the Master of Science degree in Pharmaceutical Sciences at the University of Texas, Austin. The degree would be granted at the end of the Fellowship provided that the required coursework and thesis have been completed. The recommended course of study is designed to assist the Fellow in coordinating required and recommended coursework along with the Fellowship requirements. However, the coursework is tailored based on individual interests, background and career goals. Additionally, the College is home to TxCORE (Texas Center for Health Outcomes Research and Education), which is a leader in addressing population and individual health through innovative, high-quality research, and education, and serves the community by responding to critical health care issues that impact patients’ daily lives. TxCORE combines the strengths of its nationally recognized clinical, pharmacy, social and behavioral, economics, and policy researchers to collect, analyze, and interpret data, and disseminate research findings throughout the many sectors of the health care industry, government, and private sector organizations.

The unique nature of the Baylor Scott & White integrated healthcare system, combined with the pharmacoeconomic expertise at the College of Pharmacy, offers significant opportunity for individuals interested in the Novartis Fellowship experience.

Eligibility

Eligible candidates must have a doctorate in pharmacy or the combination of an undergraduate degree in pharmacy plus an advanced degree in health services research, public health, health policy, pharmacy, economics, medicine or other related area. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred.

Information

For questions or additional information, please contact:
Xiaoxia (Summer) Wang, PharmD
Health Economics & Outcomes Research Fellow
Email: xiaoxia.wang@bswhealth.org

All questions regarding potential visa sponsorship should be directed to the collaborating institution.
First-Year Fellow:

Xiaoxia (Summer) Wang, PharmD

Xiaoxia Wang is a first-year Health Economics & Outcomes Research (HEOR) Fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH), and the University of Texas at Austin (UT Austin). Xiaoxia received her Doctor of Pharmacy degree from the University of South Carolina (USC). Her interest in HEOR stems from her background in managed care and her passion for improved patient clinical outcomes and medical access.

During her time at USC, Xiaoxia participated in several research projects in clinical outcome research and healthcare information technology. Her research projects focused on a variety of different aspects, including cost-effectiveness analysis of Alzheimer’s disease medications, medication repurposing of antidiabetic treatments, healthcare disparities, and health service utilization in the oncology area. She enjoyed working across a variety of therapeutic areas and was passionate about clinical outcome research.

Prior to her fellowship, Xiaoxia worked in multiple settings such as retail pharmacy, pharmaceutical company, and consulting company. She has been working as a market access intern at The Kineticx Group (TKG) for more than one year, where she was able to perform secondary research for newly FDA-approved oncology and rare disease treatments and conducted market research to assess the competitive landscape and assist in developing marketing plans. She also participated in business pitches and developed research protocols for real-world evidence projects, and this working experience made her very interested in pharmaceutical company and data analysis.

During the first year, Xiaoxia will collaborate with pharmaceutical companies to conduct clinical outcome and economics studies at BSWH, while supporting the Antimicrobial Stewardship and the P&T Committee. In addition, Xiaoxia is working towards earning a Master’s degree in Pharmaceutical Science from the Division of Health Outcomes and Pharmacy Practice at the University of Texas at Austin.

Second-Year Fellow:

Karishma Thakkar, PharmD

Karishma Thakkar is the second-year Health Economics & Outcomes Research (HEOR) fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH), and the University of Texas at Austin.

Karishma received her Doctor of Pharmacy degree from the University of Houston College of Pharmacy and brings to the fellowship her valuable experiences from managed care, research, hospital, and specialty pharmacy. Prior to the fellowship, Karishma interned at the Texas Children’s Health Plan, where she supported the Director of Pharmacy in strategizing ways to improve key accountable care organization metrics and health outcomes for their members. She also was involved in various research projects such as a systematic literature review and quality improvement projects where she gained experience formulating search strategies, designing data extraction protocols, and analyzing results.

During her first year at BSWH and UT Austin, she led an industry sponsored study focused on the patient journey with prurigo nodularis and supported an implementation science project assessing physician confidence in outpatient deep vein thrombosis management. She was also able to support a variety of internal research committees such as antimicrobial stewardship committee, diabetes subcommittee and the specialty taskforce, utilizing retrospective claims and electronic health record data. Some of her projects included an analysis of key performance indicators in the BSHW commercial populations, assessing antibiotic prescribing trends and comparing outcomes of antidiabetic medications to drive operational decisions at BSWH. As a result, she presented 4 posters at various conferences including AMCP and ISPOR and is in the process of publishing 2 manuscripts.

In her second year at Novartis, Karishma supports the US HE&OR Cardiovascular, Metabolic and Nephrology team. She works cross-functionally with internal and external stakeholders, working on various parts of a project from concept development to data dissemination dependent on strategic alignment. She is currently involved in multiple projects, including a retrospective claims analysis, economic modeling, and strategic preparation for launch. In addition, Karishma is also working towards earning a Master’s degree in Pharmaceutical Science from the Division of Health Outcomes and Pharmacy Practice at UT Austin.
Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, pharmacy administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.

For questions or additional information, please contact:
Charlene Tugwete, PharmD
Health Economics & Outcomes Research Fellow
Email: charlene.tugwete@jefferson.edu

All questions regarding potential visa sponsorship should be directed to the collaborating institution.
First-Year Fellow:
Charlene Tugwete, PharmD
Charlene is a first-year Health Economics & Outcomes Research (HEOR) Fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceuticals Corporation.
Charlene received her Doctor of Pharmacy from the University of Maryland, Baltimore (UMB). Her passion for HEOR developed from her wide range of experiences during her time in pharmacy school. These experiences enriched her understanding and sparked her interest in exploring the intersection of healthcare and economics. Charlene was first introduced to HEOR after participating in the AMCP Local P&T Competition in 2021. She enters the Fellowship with a variety of past experiences in research, managed care, and health policy.
Prior to the fellowship, Charlene contributed to understanding the utilization of Z-codes among oncology patients, aiming to estimate the association between social determinants of health (SDOH) and health utilization using private payer claims data. Additionally, during her Carefirst Blue Cross BlueShield rotation, she gained insight into the US payer model system and formulary decision-making.
During her first year at JCPH, Charlene will be involved in an array of projects, including manuscript writing, claims-based outcomes research, modeling, and patient registry data. Alongside these projects, she will pursue a master's degree in Applied Health Economics and Outcomes Research. Through the JCPH Fellowship, Charlene aspires to build on her knowledge of HEOR and related disciplines to further solidify her skills and contribute to enhancing patient care and access.

Second-Year Fellow:
Adaeze Amaefule, PharmD
Adaeze Amaefule is the second year Health Economics & Outcomes Research (HEOR) fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceutical Corporation.
Adaeze received her Doctor of Pharmacy from the University of Maryland School of Pharmacy. Her interest in health economics & outcomes research (HEOR) stemmed from her background in public health science, passion for improved patient outcomes, and was also sparked during her internship with Novartis. Prior to the fellowship, she was a medical affairs intern at Novartis, where she was able to work cross-functionally with the HEOR team. Adaeze completed a rotation with Bristol-Myers Squibb's US HEOR team and Xcenda, where she reviewed protocols for unmet need studies, evaluated data visualization tools for field HEOR use.
During the first year of the fellowship at Jefferson College of Population Health (JCPH), Adaeze furthered her training in HEOR through a variety of research projects which included analyzing administrative claims data, surveys, and registry data. She led outcomes research projects in kidney transplantation, major depressive disorder, employer perspectives, and oncology care quality metrics. Adaeze presented 5 research projects at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Academy of Manage Care Pharmacy (AMCP), and American Society of Clinical Oncology (ASCO).
During her second year of her fellowship at Novartis, Adaeze supports the US HEOR Solid Tumor team by managing research studies through collaboration with cross-function teams in concept development, protocol review, and strategic planning. Her research consists of qualitative research, economic modeling and retrospective claims database analyses. Adaeze is also continuing her coursework towards earning a Master's degree in applied health Economic and Outcome Research from JCPH.
Novartis Pharmaceuticals Corporation/University of Pittsburgh School of Pharmacy/UPMC Health Plan (1 position)

Fellowship Sites & Preceptors

University of Pittsburgh School of Pharmacy
Kangho Suh, PharmD, PhD, Assistant Professor, Department of Pharmacy & Therapeutics, Pittsburgh, PA

UPMC Health Plan
Chester “Bernie” Good, MD, MPH, Senior Medical Director, Center for Value-Based Pharmacy Initiatives, Pittsburgh, PA

Samuel Peasah, PhD, RPh, MBA, Director, Center for Value-Based Pharmacy Initiatives and Associate Adjunct Associate Professor, University of Pittsburgh School of Pharmacy, Pittsburgh, PA

Novartis Pharmaceuticals Corporation
Batul Electricwala, PhD, BPharm, Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

Eligible candidates must have a doctorate in pharmacy or the combination of an undergraduate degree in pharmacy plus an advanced degree in health services research, public health, health policy, pharmacy, economics, medicine or other related area. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics, or another related field of research is preferred.

For questions or additional information, please contact:
Kangho Suh, PharmD, PhD
Assistant Professor
University of Pittsburgh | School of Pharmacy
Email: KAS551@pitt.edu

All questions regarding potential visa sponsorship should be directed to the collaborating institution.
Assistant Professor: Kangho Suh, PharmD, PhD

Kangho Suh is an Assistant Professor in the Department of Pharmacy & Therapeutics in the School of Pharmacy at University of Pittsburgh. His research areas are in pharmacoepidemiology, health economics, and outcomes research. He received his PharmD from Rutgers University and then completed the Novartis HEOR fellowship at University of Texas at Austin (where he received his MS) and Scott & White Health Plan. Afterwards, he graduated with his PhD from the CHOICE Institute at University of Washington. As a previous fellow, Kangho looks forward to mentoring and growing the next generation of HEOR leaders at Pitt through the Novartis fellowship.

Currently, Kangho’s research includes assessing outcomes in drug-associated acute kidney injury, examining comparative and cost-effectiveness in second generation antipsychotics long acting injectables, and evaluating healthcare costs in chronic kidney disease. Additionally, he leads research projects for the Rx Center for Outcomes Research and Practice Implementation Excellence (RxCore) between Pitt Pharmacy and UPMC with the help of graduate students. Furthermore, he is an external member of the Institute for Clinical and Economic Review where he developed the economic models in Amyotrophic Lateral Sclerosis, nonalcoholic steatohepatitis, and currently Metachromatic Leukodystrophy.

Senior Medical Director: Chester “Bernie” Good, MD, MPH

Bernie Good is the Senior Medical Director for the Center for Value-Based Pharmacy Initiatives with UPMC Health Plan, where he provides oversight for the development, implementation, and evaluation of innovative value-based payment models for pharmaceuticals. He is also a Professor of Medicine and Pharmacy at the University of Pittsburgh where he has mentored students, residents, and fellows. He received his medical degree from George Washington University and completed an internal medicine residency at University of Pittsburgh. Prior to UPMC, he worked as a staff physician and national leader in Veterans Affairs Pharmacy Practice and Policy for 18 years, where he contributed to several research and quality improvement initiatives. He also served as technical advisor for several national organizations including CMS, FDA, and US Pharmacopeia.

Director: Samuel Peasah, PhD, RPh, MBA

Samuel Peasah is a Director at the Center for Value-Based Pharmacy Initiatives, UPMC Health Plan and an Adjunct Associate Professor at University of Pittsburgh School of Pharmacy. He received his MBA and PhD from University of Florida, and he is a fellow of the CDC Prevention Effectiveness Fellowship-a post-doctoral fellowship in health economics. He has expertise in value-based contract negotiations, implementation, assessment, and reporting, and other quality-of-care outcomes evaluation at UPMC Health Plan. Prior to his position at UPMC, he was faculty, director for the Center for Outcomes Research and Education, and director of post-graduate pharmaceutical fellowships at Mercer University College of Pharmacy in Atlanta Georgia. He has precepted and published with pharmacy students and residents at Mercer and continues to precept Pitt School of Pharmacy PharmD students and residents in health outcomes research.
Previous Fellows

Neetu Agashivala, MS
Global RWE Head, Cardiovascular Renal Metabolism,
Novartis

Lauren Bartolome, PharmD
Director, HEOR I&I,
Pfizer, Inc.

Kelly Fee Bell, PharmD, MSPhr
Value Evidence Lead,
GlaxoSmithKline

William Boyko, PharmD
Pharmacist Consultant,
P&C Pharma

Cat Bui, PharmD, PhD
Director, HEOR, Hematology,
AbbVie

Scott Bull, PharmD
Director, Clinical Development,
Johnson & Johnson

Beilei Cai, PhD, MA
Senior Director, US HEOR-Oncology,
Novartis

Aaron Carabajal-Johnson, PharmD, MS
Senior Manager, HEOR
Inovalon

Jane Chang, MPH
Senior Director, Value and Evidence,
Pfizer, Inc.

Michelle Choi, PharmD
Medical Science Liaison-Immunology,
Sanofi

Paul C. Cockrum, PharmD, DPh
North America Director, Oncology HEOR,
Ipsen Biopharma

Arijita Deb, PhD
Director, Value Evidence and Outcomes,
GlaxoSmithKline

Laurence Djatche, PharmD, MS
Director, HEOR,
Endo Pharmaceuticals

Quynh Chau Doan, PhD, MS, RPh
Director, External Strategies HEOR,
AbbVie

Joseph Doyle, MBA
Pharmacy Manager,
Dr. G’s Pharmacy

Batul Electricwala, PhD
Director, HEOR,
Novartis

John Fastenau, PhD, MPH, RPh
Senior Director, Patient Reported Outcomes,
Janssen Pharmaceuticals

Feride Frech, PhD, MPH
Senior Director, HEOR & RWE,
Eisai, Inc.

Rahul Garg, PhD
Assistant Professor,
Chicago State University

Joseph Goble, PharmD, MS
Director, Value & Evidence Scientific Engagement - Field,
Janssen Pharmaceuticals

Boris Gorsh, PharmD, MS
Value Evidence Leader,
GlaxoSmithKline

Bill Grant, PhD
Associate Professor of Economics,
College of Business,
James Madison University

Amy Grogg, PharmD
Strategic Advisor,
Vesey Street Capital Partners

Kristy Hanson, PharmD, MS
Scientific Consultant, Value Demonstration,
United BioSource Corporation: An Express Scripts Company

Peter Hur, PharmD, MBA
Director, Worldwide HEOR Inflammation and Immunology,
Pfizer, Inc.

Archi Jackson, PharmD
President,
A&S Healthcare Consulting and Analytics, Inc.

Tom Karagiannis, PharmD, MS
Director, Global Market Access and Pricing,
AbbVie

Jennifer Kim, PharmD
Director, Global Pricing and Market Access,
AstraZeneca

John Kim, PharmD
Executive Director, Head of Global Market Access,
Seagen

Nina Kim, PharmD, MS
Associate Director, Real World Value & Evidence,
Oncology,
Janssen Pharmaceuticals

Yoona Kim, PharmD, PhD
Co-founder and CEO,
Arine

John Ko, PharmD, MS
Senior Director, Value, Evidence & Development Strategy,
Beam

Amy Law, PharmD, MS
Director, HEOR,
Pfizer, Inc.

Junji Lin, PhD
Associate Director,
Jazz Pharmaceuticals

Jackie Lu, PharmD, MS
Executive Director of Marketing,
Pacira Pharmaceuticals

Mario Luong, PharmD, MPH
Director of Operations,
Optum
Geneen Graber Maxwell, PharmD
President and CEO,
Dr. G’s Pharmacy

Shilpa Mehta, PharmD
Head of Oncology Marketing - Asia Pacific,
Merck & Co, Inc

Patrick Mends, PharmD

Jeannie Menz, PharmD
Director, Content Development and Training,
Sandoz

Laetitia N’Dri, PharmD
Senior Manager, HEOR Value Evidence and Outcomes Liaison,
Boehringer Ingelheim

Gilbert C. Ngan, PharmD
Pharmacist: Part D Benefits Analyst,
CMS

Cindy Nguyen, PharmD
Senior Associate Director, HEOR Value Evidence and Outcomes Liaison,
Boehringer Ingelheim

Jennifer Nguyen, PharmD
Senior Manager, HEOR US Oncology
Novartis

Lina Nol-Heiring, BS, MBA
Therapeutics Sales Specialist,
LEO Pharma

Grace Oh, PharmD
Associate Director, WW Scientific Content and US Market Capabilities, Thoracic and Emerging Tumors,
Bristol Myers Squibb

Engels Obi, PhD
Director, Global Outcomes Research and ValueEvidence Strategy Team Lead,
Merck

Jacqueline B. Palmer, PharmD, MBA
Director, Professional Promotions Marketing,
Novartis

Jina Park, PharmD
Director, Advanced Analytics,
Komodo Health

Siyeon Natalie Park, PharmD
Enterprise Pharmacy - Clinical Carepath,
Geisinger

Shivangi Patel, PharmD
Senior Manager, Patient-Centered Outcomes Research, Global Market Access,
Sarepta Therapeutics

Hoa T. Pham, PharmD
Senior Director, Field HEOR,
Beigene

Ngan Pham, PharmD
Senior Consultant,
IQVIA

Craig Plauschinat, PharmD, MPH
Director, HEOR & RWE,
Eisai, Inc.

Shibani Pokras, MPH
Senior Director, Oncology Cell Therapy,
GlaxoSmithKline

Karim Prasia, PharmD, MS
VP, Clinical Analytics and Research,
Magellan Health Services

Karina Raimundo, BS Pharmacy, MS
Director, HEOR,
Genentech, Inc.

Swetha Raparla, MS
Analytics Consultant,
Cigna

David Ray, PharmD, MBA, MPH
Executive Director, Global HEOR,
Karyopharm Therapeutics, Inc.

Seon Young Ryu, PharmD
Mom/Independent Consulting,
Previously at Genentech

Rahul Sasané, PhD, MS, BPharm
Head – Global HEOR-RWE & Reimbursement,
Cerevel Therapeutics, LLC

Veronica Sendersky, PharmD
Managing Director,
Excellentia Pharma Consulting

Amishi Shah,
Associate Director, Oncology Digital Engagement & Channel Strategy,
Merck

Hemal Shah, PharmD
President/Founder,
Value Matters, LLC

Karishma Shelley, PharmD
Associate Director, HEOR - US Market, Oncology,
Bristol Myers Squibb

Slaven Sikirica, MS
Senior Director,
Lexicon Pharmaceuticals, Inc.

Anh Singhania, PharmD
Senior Director, Health Systems & Outcomes,
Medical Affairs
Intercept Pharmaceuticals

Liz Stanley Smart, MPH
Senior Associate Director, HEOR,
Boehringer Ingelheim

Bhavini Patel Srivastava, MS, BS Pharmacy
Director, HEOR,
AbbVie

Kangho Suh, PharmD, PhD, MS
Assistant Professor,
University of Pittsburgh

Dusica Tasic, MS, BS Pharmacy
Health Economics Manager, Global Marketing, GE Healthcare

Devi Thaker, PharmD, MS
Director, PharmacoAnalytics,
Express Scripts

Ryan Thalifdeen, PharmD, MS
Senior Manager, Global Value & Access
Gilead

Melody Tran, PharmD, MS
Medical Outcomes Liaison,
Abbott Laboratories
Yuen Tsang, PharmD, MPH
Associate Director, Real World Value & Evidence, Janssen Pharmaceuticals

Stuart Turner, MPH
Executive Director Global Real World Evidence & Data Science - Solid Tumors, Novartis

Stefan Varga, PharmD, MSc
director, WW HEOR, Bristol Myers Squibb

Ashok Vegesna, PharmD, MS
Director, National Accounts (Central US), Novartis

Joel Wallace, PharmD, MPH, MBA
Head, Global HEOR, Market Access and Business Strategy, Exelixis

Alexandra Wallem, PharmD,
Associate Director: Outcomes Liaison, Eli Lilly

Pin Xiang, PharmD
Director of HEOR Value Demonstration - CNS, Boehringer Ingelheim

Esther Yi, PharmD, MS
Director, Value & Evidence Inflammation and Immunology Pfizer

Krista Yokoyama, PharmD
Senior Manager, Pharmacy Analytics, Blue Shield of California

Jing Yuan, PhD
Associate Professor, Fudan University
HEOR Fellowship Application Form

Please type or print Date ________________

Name: __________________________________________________________________________

Last First MI

Address: ________________________________________________________________

Street City State Zip Code

Phone: _________________________________________________________________________

Primary Secondary

Email: ________________________________________________________________________

Undergraduate and Graduate Degree(s) (date received or expected):

______________________________________________________________________________

______________________________________________________________________________

2-Year Programs (Preferred Degrees: PharmD, PhD, MS)

Please check any site(s) of interest:

_____ Baylor Scott & White Health/The University of Texas at Austin/Novartis Pharmaceuticals Corporation

_____ Thomas Jefferson University College of Population Health/Novartis Pharmaceuticals Corporation

_____ University of Pittsburgh School of Pharmacy/UPMC Health Plan/Novartis Pharmaceuticals Corporation

Application Process (rolling submission, application deadline is October 20th, 2023 at 11:59 pm EDT):

To apply, please email usheor.fellowship@novartis.com and include the following materials:

• CV

• Application form with first-year fellowship site(s) preference

• Cover Letter

• Email of 2 References

If offered an interview, the following documents will be requested:

• 2 Letters of Recommendation (sent via email from references)

• Unofficial Transcript

Requirements:

Graduate degree in a relevant discipline focused on pharmacy, health services research, health economics, epidemiology, or a related discipline (e.g., PharmD, PhD, MPH, etc.). A background in pharmacy or medicine and experience in outcomes research, health economics, or another related field of research is preferred. Excellent communication skills (oral and written). Demonstrated success in working in teams and independently.

Please email or send the required application materials to:

Batul Electricwala, PhD, BPharm
Director, HE&OR and HE&OR Fellowship Director
Email: usheor.fellowship@novartis.com